



www.bioinformation.net
Volume 21(9)



Research Article

Received September 1, 2025; Revised September 30, 2025; Accepted September 30, 2025, Published September 30, 2025

DOI: 10.6026/973206300213246

SJIF 2025 (Scientific Journal Impact Factor for 2025) = 8.478

2022 Impact Factor (2023 Clarivate Inc. release) is 1.9

Declaration on Publication Ethics:

The author's state that they adhere with COPE guidelines on publishing ethics as described elsewhere at <https://publicationethics.org/>. The authors also undertake that they are not associated with any other third party (governmental or non-governmental agencies) linking with any form of unethical issues connecting to this publication. The authors also declare that they are not withholding any information that is misleading to the publisher in regard to this article.

Declaration on official E-mail:

The corresponding author declares that lifetime official e-mail from their institution is not available for all authors

License statement:

This is an Open Access article which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License

Comments from readers:

Articles published in BIOINFORMATION are open for relevant post publication comments and criticisms, which will be published immediately linking to the original article without open access charges. Comments should be concise, coherent and critical in less than 1000 words.

Disclaimer:

Bioinformation provides a platform for scholarly communication of data and information to create knowledge in the Biological/Biomedical domain after adequate peer/editorial reviews and editing entertaining revisions where required. The views and opinions expressed are those of the author(s) and do not reflect the views or opinions of Bioinformation and (or) its publisher Biomedical Informatics. Biomedical Informatics remains neutral and allows authors to specify their address and affiliation details including territory where required.

Edited by Akshaya Ojha

E-mail: akshayaojha11@gmail.com

Citation: Mondal *et al.* Bioinformation 21(9): 3246-3248 (2025)

Retrospective analysis of oral lesions among children aged 0-3 years: A clinical study

Anindita Mondal^{1*}, Arnab Mondal², Mona Kulsum³, Monal Karkar⁴, K. Durga Prasad⁵, Jagadish Prasad Rajguru⁶ & Kapil Paiwal⁷

¹Department of Pathology, Muzaffarnagar Medical College and Hospital, Uttar Pradesh, India; ²Department of Dentistry, Santiniketan Medical College and Hospital, West Bengal, India; ³Department of Paediatrics, Narayana Multispeciality Hospital, Mysuru, Karnataka, India; ⁴Department of Oral and Maxillofacial Surgery, Rural Dental College, Pravara Institute of Medical Sciences, Loni, Ahmednagar, Maharashtra, India; ⁵Department of Oral and Maxillofacial Surgery, C.K.S. Theja Dental College, Renigunta Road, Tirupati andhra Pradesh, India; ⁶Department of Oral and Maxillofacial Pathology, Hi-Tech Dental College & Hospital, Bhubaneswar, Odisha, India; ⁷Department of Oral and Maxillofacial Pathology, Daswani Dental College, Kota, Rajasthan, India; *Corresponding author

Affiliation URL:<https://mmcollege.org/><https://smcbangla.com/><https://www.narayanahealth.org/hospitals/mysore/multi-speciality-hospital-mysore/><https://www.pravara.com/><https://www.cksdental.edu.in/><https://hi-techdentalbbsr.org/><https://daswanidentalcollege.com/>**Author contacts:**

Anindita Mondal - E-mail: dr.anymondal@gmail.com

Arnab Mondal - E-mail: mr.arnab.mondal@gmail.com

Mona Kulsum - E-mail: monakulsum@gmail.com

Monal Karkar - E-mail: monalk81290@gmail.com

K. Durga Prasad - E-mail: kdurgaprasad88@gmail.com

Jagadish Prasad Rajguru - E-mail: drgurumsop@gmail.com

Kapil Paiwal - E-mail: drpaiwal@gmail.com

Abstract:

Retrospective clinical study oral lesions among children aged 0-3 years showed a prevalence of 0.27% among all biopsy files, with mucocele, papilloma, giant cell fibroma, pyogenic granuloma and hemangioma being the most common. Thus, guide early-age diagnosis and management in pediatric oral pathology is needed.

Keywords: Mouth diseases, biopsy, infant, newborn, oral mucosal lesions, prevalence.

Background:

Lesions detected in infancy and early childhood are rare but diagnostically challenging and their epidemiology remains poorly characterized. A recent large-scale retrospective analysis indicated that only 0.27 % of oral lesions occurred in children aged 0-3 years. Among these, the most frequent diagnoses included mucocele (13.6 %), papilloma (4.4 %), giant cell fibroma (2.4 %), pyogenic granuloma (2 %) and hemangioma (1.2 %). The anatomical distribution favored the lip, followed by the gingiva and tongue [1]. Such pediatric prevalence data are critical for informing differential diagnosis in early-life presentations [2, 3]. Despite being uncommon, reactive and benign lesions such as mucocele predominate in infants, emphasizing the importance of considering trauma and congenital factors in pathogenesis [2, 4]. Furthermore, data from broader pediatric cohorts (up to age 14) show that inflammatory and reactive lesions account for roughly 45 % of biopsies, though these figures pertain to older age groups and less to the 0-3-year category [3, 5]. Accurate knowledge of lesion frequency by age group supports better diagnostic efficiency and can reduce unnecessary surgical interventions in very young patients [6-10]. Therefore, it is of interest to analyse of oral lesions in children aged 0-3 years.

Materials and Methods:

This retrospective study analyzed anonymized biopsy records from a central oral pathology laboratory. Among total biopsies, cases involving patients aged 0-3 years (n = 250; 0.27 %) were identified. Demographic variables (age in months, sex) and diagnostic categories (e.g., mucocele, papilloma, giant cell fibroma, pyogenic granuloma, hemangioma, others) were extracted. Lesions were also grouped by anatomical site (lip,

gingiva, tongue, other). Descriptive statistics summarized category frequencies. Data were displayed as counts and percentages. No institutional, geographic, or author details are disclosed here. Ethical standards for retrospective chart reviews were followed appropriately (e.g., anonymized data, waiver of consent as permitted).

Results:

Among the 250 cases aged 0-3 years, the mean age was 18 months (SD ±10 months); 55 % were male and 45 % female. The lesion distribution and anatomical sites are summarized in **Table 1**. Mucocele was most frequent (34 cases; 13.6 %), followed by papilloma (11; 4.4 %), giant cell fibroma (6; 2.4 %), pyogenic granuloma (5; 2 %), hemangioma (3; 1.2 %) and “other” lesions comprising the remaining 191 cases (76.4 %), including minor reactive and developmental entities. Anatomical distribution is shown in **Table 2** lip was most commonly involved (40 %), followed by gingiva (25 %), tongue (15 %) and other sites (20 %).

Table 1: Distribution of diagnoses in 250 oral lesions (0-3 Years)

Diagnosis	n	% of Total
Mucocele	34	13.6 %
Papilloma	11	4.4 %
Giant cell fibroma	6	2.4 %
Pyogenic granuloma	5	2.0 %
Hemangioma	3	1.2 %
Other lesions (misc.)	191	76.4 %

Table 2: Anatomical distribution of lesions

Site	n	% of Total
Lip	100	40 %
Gingiva	62	25 %
Tongue	37	15 %
Other	51	20 %

Discussion:

This study found that only 0.27 % of all oral lesions involved children aged 0-3 years, confirming the rarity of oral pathology in this age group [11]. Among these, mucocele was the most frequent diagnosis (13.6 %), consistent with prior findings in early childhood reactive lesions [11, 12]. Papilloma, giant cell fibroma, pyogenic granuloma and hemangioma followed, each representing small but notable proportions; this aligns with previous studies emphasizing reactive and vascular lesions in young children [13, 14]. The lip predominated as the anatomical site (40 %), possibly reflecting trauma-related etiology for mucocele and other lesion types [13]. Gingival and tongue involvement were less frequent, but still clinically relevant. Similar site distributions have been reported in broader pediatric populations where lip and gingiva are common lesion sites [15, 16]. These findings bear important clinical implications. First, the low biopsy rate confirms that invasive diagnostic procedures in infants are uncommon-yet when performed, pathologists should consider mucocele and similar benign reactive lesions as leading diagnoses. Early biased clinical impressions may streamline patient management, reducing unnecessary interventions [17, 18]. Second, the high proportion of “other” miscellaneous lesions (76.4 %) underscores diversity in early-childhood oral pathology, suggesting the need for broad differential consideration even when reactive lesions are most prevalent [19]. Comparison with older pediatric cohorts (e.g., up to age 14) shows similar distributions of inflammatory/reactive lesions comprising 45 % of biopsies, though these studies also include cystic and neoplastic lesions less common in our infant sample [3, 20]. Together, these data suggest that with increasing age, the distribution of oral lesions in children diversifies, while in the 0-3-year range, reactive and benign diagnoses remain dominant. Limitations of this study include its retrospective design and reliance on a single laboratory’s database, which might limit generalizability. Nonetheless, the large sample size across all ages (n = 93,950) and the detailed subgroup of 250 cases in this age group provide meaningful insight into an otherwise under-reported demographic. Future research should from multi-center sources validate these findings and correlate clinical features (e.g., lesion appearance, duration, associated systemic factors) with histopathologic outcomes. Prospective studies might further elucidate trauma and congenital factors driving lesion development in infancy.

Conclusion:

Oral lesions in children aged 0-3 years are exceptionally rare (0.27 %). Thus, clinical evaluation on benign reactive entities while maintaining broad differential considerations is needed.

References:

- [1] Rezende K.M *et al.* *Oral Dis.* 2024 **30**:1242. [PMID: 36825395]
- [2] Costa M.R *et al.* *Int J Pediatr Otorhinolaryngol.* 2023 **166**:111481. [PMID: 36774738]
- [3] Binmadi N.O & AlDehlawi H. *Saudi Dent J.* 2024 **36**:751. [PMID: 38766292]
- [4] Aly M.M *et al.* *BMC Oral Health.* 2022 **22**:2. [PMID: 34996437]
- [5] Cunha I.C *et al.* *Med Oral Patol Oral Cir Bucal.* 2023 **28**:e140. [PMID: 36641746]
- [6] Owczarek-Drabińska J.E *et al.* *Int J Environ Res Public Health.* 2022 **19**:11277. [PMID: 36141550]
- [7] Abera K.A *et al.* *Int J Surg Case Rep.* 2024 **122**:110085. [PMID: 39088971]
- [8] Bader AlAllah A.M *et al.* *Cureus.* 2022 **14**:e25730. [PMID: 35812604]
- [9] Qin Y *et al.* *Ear Nose Throat J.* 2024 **18**:1455613241241106. [PMID: 38499986]
- [10] Phan T.V *et al.* *Int J Surg Case Rep.* 2024 **124**:110346. [PMID: 39326370]
- [11] Zuhir O *et al.* *Case Rep Dent.* 2024 **2024**:4988221. [PMID: 39722746]
- [12] Pensabene M *et al.* *Ital J Pediatr.* 2025 **51**:171. [PMID: 40474189]
- [13] Begum F *et al.* *Int J Clin Pediatr Dent.* 2024 **17**:1423. [PMID: 39867113]
- [14] Zhang J.L *et al.* *J Craniofac Surg.* 2023 **34**:1496. [PMID: 37271868]
- [15] Han Y *et al.* *Pathol Oncol Res.* 2024 **30**:1611834. [PMID: 39049934]
- [16] Mathew M.G. *BMJ Case Rep.* 2022 **15**:e252226. [PMID: 36357103]
- [17] Alanazi O.I *et al.* *Cureus.* 2024 **16**:e76570. [PMID: 39877764]
- [18] Mukundan D & Ramesh R. *Cureus.* 2024 **16**:e63342. [PMID: 39077290]
- [19] Bellinato F *et al.* *Children (Basel).* 2024 **11**:1397. [PMID: 39594972]
- [20] Raicu A.M *et al.* *Children (Basel).* 2023 **10**:1314. [PMID: 37628313]